Tirzepatide in Type 1 Diabetes: Cardiometabolic Effects(TIRTLE)
- Conditions
- Type 1 DiabetesMetabolic and Endocrine - Diabetes
- Registration Number
- ACTRN12624000111572
- Lead Sponsor
- Garvan Institute of Medical Research
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 24
•age 18-60 years
•2 years since diagnosis of type 1 diabetes
•BMI greater than or equal to 30 kg/m2
•Willingness to give written informed consent, participate and comply with the study.
•treatment with a glucagon-like peptide-1 (GLP1) receptor agonist, or a sodium-glucose cotransporter 2 (SGLT2) inhibitor in the last 6 weeks
•treatment with glucocorticoids in the last 6 weeks
•previous bariatric surgery or planned during the trial period
•diabetic ketoacidosis or severe hypoglycaemia in the last 3 months
•eGFR <45 ml/min/1.73m2
•evidence of significant liver disease (known cirrhosis, LFTs > 3x upper limit of normal)
•known gastroparesis
•history of pancreatitis or cholecystitis
•pregnant, breastfeeding or female of childbearing potential not using adequate contraception
•coronary event or stroke in the last 3 months
•history of active proliferative diabetic retinopathy or macular oedema
•cognitive impairment or significant psychiatric illness which impairs ability to understand study requirements
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Weight (kg)[Digital scale change from baseline (taken prior to commencement of treatment) and after 12 weeks post commencement of treatment ]
- Secondary Outcome Measures
Name Time Method